NASDAQ:APEN - Apollo Endosurgery Stock Price, Forecast & News

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

Apollo Endosurgery Inc (NASDAQ:APEN) announced its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported ($0.40) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.42) by $0.02. The biotechnology company had revenue of $11.26 million for the quarter, compared to the consensus estimate of $13.37 million. Apollo Endosurgery had a negative net margin of 71.59% and a negative return on equity of 176.86%. View Apollo Endosurgery's Earnings History.

Apollo Endosurgery is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Apollo Endosurgery.

News stories about APEN stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Apollo Endosurgery earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Apollo Endosurgery.

Apollo Endosurgery saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 170,500 shares, an increase of 6.7% from the December 15th total of 159,800 shares. Based on an average trading volume of 14,600 shares, the short-interest ratio is currently 11.7 days. Currently, 1.3% of the shares of the company are short sold. View Apollo Endosurgery's Current Options Chain.

Some companies that are related to Apollo Endosurgery include Restoration Robotics (HAIR), Soliton (SOLY), Repro-Med Systems (REPR), Repro Med Systems (KRMD), iCAD (ICAD), Venus Concept (VERO), TELA Bio (TELA), Cytosorbents (CTSO), Spectral Medical (EDTXF), BRAINSWAY LTD/S (BWAY), Liquidia Technologies (LQDA), BeyondAirInc . (XAIR), Neuronetics (STIM), Nephros (NEPH) and STRATA Skin Sciences (SSKN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Corbus Pharmaceuticals (CRBP), Second Sight Medical Products (EYES), Genocea Biosciences (GNCA), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), NovaBay Pharmaceuticals (NBY) and Arbutus Biopharma (ABUS).

Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of APEN stock can currently be purchased for approximately $2.85.

Apollo Endosurgery has a market capitalization of $59.69 million and generates $60.85 million in revenue each year. The biotechnology company earns $-45,790,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. Apollo Endosurgery employs 215 workers across the globe.View Additional Information About Apollo Endosurgery.

The official website for Apollo Endosurgery is http://www.apolloendo.com/.

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]